Background:Oral cancers, with oral squamous cell carcinoma (OSCC) as
the predominant type, have a significant impact on morbidity and mortality rates. Therefore,
targeting the NFκB pathway shows promise in cancer therapy.Materials and Methods:This study investigated the impact of two NFκB inhibitors,
LY2409881 and MLN4924, on cell proliferation, apoptosis susceptibility, and in vivo tumorigenesis
in OSCC cell lines CAL27 and SCC15.Results:The results revealed that both LY2409881 and MLN4924 effectively suppressed
cell proliferation, induced apoptosis, and arrested the cell cycle at the G2/M
phase—a phenomenon likely associated with the NFκB pathway. Furthermore, MLN4924
demonstrated potent inhibitory effects on cell proliferation at low μM concentrations,
surpassing the effectiveness of LY2409881 as an inhibitor. (All results: p<0.05)Conclusion:These findings highlight the potential of LY2409881 and MLN4924 as novel
therapeutic agents for OSCC, thereby offering new insights for the clinical management
of this condition.